Login
$TLSI
$2.27 +$0.00 (0.0%) After hours

Company Executives

Officer Age In this role 2025 pay Source
Mary Szela Also a director
Chief Executive Officer, President and Director
62 Not stated $4,823,349
David Patience
Chief Financial Officer
40 Since 2025
1 year
$3,443,628
Jennifer Stevens
Chief Regulatory Officer
Title from the Form 4 dated Oct 5, 2026
65 Not stated Not reported
Richard Marshak
Chief Commercial Officer
67 Since 2025
1 year
$1,556,000
Richard Marshall
Chief Medical Officer
Title from the Form 8-K dated Jun 29, 2026
Not stated Not stated Not reported
Bryan Cox
Chief of Research
64 Since 2020
6 years
Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
6 of 6
stated in the proxy; 1 not stated
Average tenure
3.9 years
from year joined
CEO also chairs the board
No
Mats Wahlström
Director Age On board Independent Other public boards 2025 pay Source
Mats Wahlström
71 2017
9 years
Independent Coherus Oncology, Inc. $138,749
Mary Szela
62 2018
8 years
Not stated Kura Oncology, AbSci, Averin Capital Paid as CEO
Gary Gordon
73 2025
1 year
Independent None stated $220,085
Kerry Hicks
66 2021
5 years
Independent None stated $116,249
William Valle
65 2025
1 year
Independent None stated $240,710
Michael P. Stansky
67 2026
this year
Independent None stated Not stated
David J. Matlin
64 2023
3 years
Independent Clene, Inc. $128,748

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

6 disclosed in the proxy filed Mar 31, 2026
Dr. Desai
a member of the Board at the time of the Offer
Amount not stated
2024

Exchanged 246,667 Exchange Warrants for 74,000 shares of Common Stock in the warrant exchange offer.

Frankenius Equity AB
a holder of greater than 5% of TriSalus capital stock
Amount not stated

Purchased 62,972 shares of Common Stock in the December 2024 private placement.

Mr. Dewey
a holder of greater than 5% of TriSalus capital stock as of the purchase date
Amount not stated

Purchased 50,377 shares of Common Stock in the December 2024 private placement.

Mr. Wahlström
the Chairman of our Board
Amount not stated

Purchased 25,188 shares of Common Stock in the December 2024 private placement.

Mr. Pallotta
a holder of greater than 5% of TriSalus capital stock as of the purchase date
Amount not stated

Purchased 200,000 shares of Common Stock in the April 2025 private placement.

Mr. Dewey
a holder of greater than 5% of TriSalus capital stock as of the purchase date
Amount not stated

Purchased 62,500 shares of Common Stock in the April 2025 private placement.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support